HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kompella, U. B. Articles by Ayalasomayajula, S. P. Search for Related Content PubMed PubMed Citation Articles by Kompella, U. B. Articles by Ayalasomayajula, S. P.

Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capable of Inhibiting VEGF Expression

¹From the Departments of Pharmaceutical Sciences and ²Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska.

PURPOSE. The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels.

METHODS. The effect of budesonide (100 pM to 10 µM) on VEGF secretion, expression of VEGF mRNA, and cytotoxicity were determined in ARPE-19 cells by ELISA, RT-PCR, and a cell-viability assay, respectively. To determine the involvement of glucocorticoid receptor in the observed effects of budesonide, secretion and mRNA expression studies were also performed in the presence of a glucocorticoid receptor antagonist (RU486). DL-Polylactide (PLA) nano- and microparticles containing budesonide were prepared by a solvent evaporation technique, and the particles were characterized for size, morphology, encapsulation efficiency, and in vitro release. Budesonide-PLA nano- and microparticles were administered subconjunctivally to one eye of Sprague-Dawley rats and drug levels in the retina, vitreous, lens, and cornea of both eyes were determined at the end of 1, 7, and 14 days.

RESULTS. At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells in a dose-dependent manner. RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression. Budesonide-PLA nano- (345 nm) and microparticles (3.6 µm), with an encapsulation efficiency of 65% and 99%, respectively, sustained budesonide release in vitro. After subconjunctival administration, both budesonide-PLA nano- and microparticles produced sustained budesonide levels in the retina and other ocular tissues.

CONCLUSIONS. Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity. Subconjunctivally administered budesonide-PLA nano- and microparticles sustain retinal drug delivery.

This article has been cited by other articles:

				J. A. Cardillo, F. Paganelli, L. A. S. Melo Jr, A. A. Silva Jr, A. C. Pizzolitto, A. G. Oliveira, and the Brazilian Ocular Pharmacology and Pharmaceutic Subconjunctival Delivery of Antibiotics in a Controlled-Release System: A Novel Anti-infective Prophylaxis Approach for Cataract Surgery Arch Ophthalmol, January 1, 2010; 128(1): 81 - 87. [Abstract] [Full Text] [PDF]

				F. Paganelli, J. A. Cardillo, L. A. S. Melo Jr, D. R. Lucena, A. A. Silva Jr, A. G. Oliveira, A. L. Hofling-Lima, Q. D. Nguyen, B. D. Kuppermann, R. Belfort Jr, et al. A Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3041 - 3047. [Abstract] [Full Text] [PDF]

				J. Y. Tsui, C. Dalgard, K. R. Van Quill, L. Lee, H. E. Grossniklaus, H. F. Edelhauser, and J. M. O'Brien Subconjunctival Topotecan in Fibrin Sealant in the Treatment of Transgenic Murine Retinoblastoma Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 490 - 496. [Abstract] [Full Text] [PDF]

				A. C. Amrite, H. F. Edelhauser, and U. B. Kompella Modeling of Corneal and Retinal Pharmacokinetics after Periocular Drug Administration Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 320 - 332. [Abstract] [Full Text] [PDF]

				N. P. S. Cheruvu, A. C. Amrite, and U. B. Kompella Effect of Eye Pigmentation on Transscleral Drug Delivery Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 333 - 341. [Abstract] [Full Text] [PDF]

				A. M. Carcaboso, G. F. Bramuglia, G. L. Chantada, A. C. Fandino, D. A. Chiappetta, M. T. G. de Davila, M. C. Rubio, and D. H. Abramson Topotecan Vitreous Levels after Periocular or Intravenous Delivery in Rabbits: An Alternative for Retinoblastoma Chemotherapy Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3761 - 3767. [Abstract] [Full Text] [PDF]

				P. D. Jani, N. Singh, C. Jenkins, S. Raghava, Y. Mo, S. Amin, U. B. Kompella, and B. K. Ambati Nanoparticles Sustain Expression of Flt Intraceptors in the Cornea and Inhibit Injury-Induced Corneal Angiogenesis Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2030 - 2036. [Abstract] [Full Text] [PDF]

				N. P. S. Cheruvu and U. B. Kompella Bovine and Porcine Transscleral Solute Transport: Influence of Lipophilicity and the Choroid-Bruch's Layer. Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4513 - 4522. [Abstract] [Full Text] [PDF]

				A. C. Amrite, S. P. Ayalasomayajula, N. P. S. Cheruvu, and U. B. Kompella Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1149 - 1160. [Abstract] [Full Text] [PDF]

				H. Tamura, K. Miyamoto, J. Kiryu, S. Miyahara, H. Katsuta, F. Hirose, K. Musashi, and N. Yoshimura Intravitreal Injection of Corticosteroid Attenuates Leukostasis and Vascular Leakage in Experimental Diabetic Retina Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1440 - 1444. [Abstract] [Full Text] [PDF]